Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.210
Sell
RSI(14)
43.460
Neutral
STOCH(KDJ)(9,3,3)
64.306
Neutral
ATR(14)
1.664
Low Volatility
CCI(14)
-51.060
Neutral
Williams %R
57.338
Sell
TRIX(12,20)
-0.347
Sell
StochRSI(14)
8.456
Sell
Search
Viking Therapeutics Inc
VKTXAdd to Watchlist
31.320USD
-0.400-1.26%
Close 05/12, 16:00（ET）Quotes delayed by 15 min
3.63BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Viking Therapeutics Inc
Currency: USD Updated: 2026-05-11Key Insights
Viking Therapeutics Inc's fundamentals are relatively very weak, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 165 out of 383 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 94.12.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Viking Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Viking Therapeutics Inc Highlights
StrengthsRisks
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -7.63, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 84.26M shares, decreasing 9.55% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 1.60K shares of this stock.
Analyst Rating
Based on
19
analysts
Buy
Current Rating
94.125
Target Price
+200.43%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-11The current financial score of Viking Therapeutics Inc is 3.80, ranking 383 out of 383 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.
Score
Financials
0.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
5.28
Operational Efficiency
4.00
Growth Potential
4.70
Shareholder Returns
5.00
Viking Therapeutics Inc's Company Valuation
Currency: USD Updated: 2026-05-11The current valuation score of Viking Therapeutics Inc is 6.94, ranking 188 out of 383 in the Biotechnology & Medical Research industry. Its current P/E ratio is -7.63, which is -5.42% below the recent high of -7.22 and -1259.61% above the recent low of -103.80.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 165/383
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-11The current earnings forecast score of Viking Therapeutics Inc is 8.53, ranking 106 out of 383 in the Biotechnology & Medical Research industry. The average price target is 100.50, with a high of 125.00 and a low of 36.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
19
analysts
Buy
Current Rating
94.125
Target Price
+200.43%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Viking Therapeutics Inc
VKTX
19
CRISPR Therapeutics AG
CRSP
29
Beigene Ltd
ONC
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-11The current price momentum score of Viking Therapeutics Inc is 7.23, ranking 116 out of 383 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 36.07 and the support level at 28.10, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
31.646
Sell
MA10
31.381
Sell
MA20
32.724
Sell
MA50
33.309
Sell
MA100
32.806
Sell
MA200
32.722
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-11The current institutional shareholding score of Viking Therapeutics Inc is 7.00, ranking 83 out of 383 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 72.58%, representing a quarter-over-quarter increase of 10.67%. The largest institutional shareholder is Steven Cohen, holding a total of 313.49K shares, representing 0.27% of shares outstanding, with 1.00% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-11The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Viking Therapeutics Inc. The Biotechnology & Medical Research industry's average is 3.36. The company's beta value is 0.69. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.69
VaR
+6.45%
240-Day Maximum Drawdown
+45.14%
240-Day Volatility
+83.57%
Return
Best Daily Return
60 days
+11.05%
120 days
+11.89%
5 years
+121.02%
Worst Daily Return
60 days
-8.00%
120 days
-11.06%
5 years
-42.12%
Sharpe Ratio
60 days
+0.47
120 days
-0.49
5 years
+0.76
Risk Assessment
Maximum Drawdown
240 days
+45.14%
3 years
+78.86%
5 years
+78.86%
Return-to-Drawdown Ratio
240 days
+0.34
3 years
+0.43
5 years
+1.04
Skewness
240 days
-2.74
3 years
+7.88
5 years
+7.37
Volatility
Realised Volatility
240 days
+83.57%
5 years
+85.50%
Standardised True Range
240 days
+6.21%
5 years
+5.64%
Downside Risk-Adjusted Return
120 days
-80.55%
240 days
-80.55%
Maximum Daily Upside Volatility
60 days
+45.23%
Maximum Daily Downside Volatility
60 days
+37.30%
Liquidity
Average Turnover Rate
60 days
+2.24%
120 days
+2.45%
5 years
--
Turnover Deviation
20 days
-42.63%
60 days
-38.39%
120 days
-32.57%
Peer Comparison
Biotechnology & Medical Research
Viking Therapeutics Inc
VKTX
5.84 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.74 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AnaptysBio Inc
ANAB
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
